Gabapentin

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Gabapentin

Examples of brand names: Neurontin [DE]

ATC code: N02BF01

Main use (for orientation): Neuropathic pain; epilepsy

Documented research summary

Controlled human experiment (n=8) with gabapentin 600/1200 mg and oral THC 5–30 mg: the combination enhanced several cannabinoid-sensitive and performance-related effects. CBD cohort CL20 showed no significant association with gabapentin concentrations. Nabilone add-on RCT (n=15) showed analgesia with frequent dizziness/drowsiness, not pharmacokinetic evidence.

Uncertainties and limitations

2025 case report: acute confusion/inability to walk after starting gabapentin with heavy THC use; polypharmacy limits causal interpretation. No CYP-mediated breakdown, so no established CYP-related gabapentin increase.

Separately recorded findings

1 separately recorded finding. Each statement applies to its documented study context.

CBD – clinical signals

Finding ID: B0063

Type of result: No / minor effect under the conditions studied

Observation: No concentration signal; p=0.8160.

Mechanism: PK observation

Study type: Observational study: no signal detected

Context studied: n=7.

Clinical interpretation: Not ruled out

Limitations and uncertainties: Context / limitations of CL20; a lack of statistical significance does not establish equivalence.

Original sources for this finding: Final analysis of potential drug-drug interactions between highly purified cannabidiol and anti-seizure medications in an open-label expanded access program [CL20]

References and access status

[CA_L_D0062] GABAPENTIN (GABAPENTIN) CAPSULE [REMEDYREPACK INC.]

Original source / bibliographic reference

Authors: REMEDYREPACK INC.

Year: 2026

Source type: Current published human-use SPL / product information

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[CL20] Final analysis of potential drug-drug interactions between highly purified cannabidiol and anti-seizure medications in an open-label expanded access program

Original source / bibliographic reference

Authors: Gaston TE; Bebin EM; Cutter GR; Grayson L; Szaflarski JP

Year: 2023

Source type: Open-label longitudinal observational study

DOI: 10.1002/epi4.12815

PMID: 37593907

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

PubMed – bibliographic reference / abstract

DOI – publisher access (access restrictions may apply)

Europe PMC – full-text access according to the literature database – Listed as freely available HTML full text in the official Europe PMC metadata. Direct retrieval was not fully verified here.

[CA_P_26313650] Separate and combined effects of gabapentin and [INCREMENT]9-tetrahydrocannabinol in humans discriminating [INCREMENT]9-tetrahydrocannabinol.

Original source / bibliographic reference

Authors: Lile JA, Wesley MJ, Kelly TH, Hays LR.

Year: 2016

Source type: research-article; Journal Article; Research Support, N.I.H., Extramural

DOI: 10.1097/fbp.0000000000000187

PMID: 26313650

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

[CA_P_25288189] Nabilone as an adjunctive to gabapentin for multiple sclerosis-induced neuropathic pain: a randomized controlled trial.

Original source / bibliographic reference

Authors: Turcotte D, Doupe M, Torabi M, Gomori A, Ethans K, Esfahani F, Galloway K, Namaka M.

Year: 2015

Source type: Research Support, Non-U.S. Gov't; Randomized Controlled Trial; Journal Article

DOI: 10.1111/pme.12569

PMID: 25288189

Source access – 23 October 2026: Direct retrieval could not be fully verified; availability remains unresolved.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

[CA_P_40225514] Cannabis and Polypharmacy Leading to Hospitalization for Acute Confusion and Inability to Ambulate.

Original source / bibliographic reference

Authors: McKnight L, Widman JJ.

Year: 2025

Source type: Journal Article; Case Reports; case-report

DOI: 10.7759/cureus.80481

PMID: 40225514

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

PubMed Central – full-text access according to the literature database – Archive attribution confirmed by Europe PMC metadata. Direct retrieval was not fully verified here; access may require a browser check.

Europe PMC – full-text access according to the literature database – Listed as freely available HTML full text in the official Europe PMC metadata. Direct retrieval was not fully verified here.

[CA_P_31377197] Acute effect of cannabidiol on the activity of various novel antiepileptic drugs in the maximal electroshock- and 6 Hz-induced seizures in mice: Pharmacodynamic and pharmacokinetic studies.

Original source / bibliographic reference

Authors: Socała K, Wyska E, Szafarz M, Nieoczym D, Wlaź P.

Year: 2019

Source type: Research Support, Non-U.S. Gov't; Journal Article

DOI: 10.1016/j.neuropharm.2019.107733

PMID: 31377197

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility